Disclosed herein are methods of performing multiplexed serological immunoassays to detect multiple antigens in parallel to determine if a patient has an infection or an immune disorder. Use of multiple antigens in parallel increases specificity and/or sensitivity towards assaying the infection or immune disorder. The infection may be a viral infection such as a SARS-CoV-2 viral infection, a variant of a SARS-CoV-2 viral infection, or a non-SARS-CoV-2 coronavirus infection. Also disclosed herein are methods of performing the multiplexed serological immunoassays on an optical ring resonator substrate. Also disclosed herein are methods of detecting antibodies specific for an antigen that belong to more than one immunoglobulin type.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and/or a base unit for obtaining a sensitive readout of the immunoassay results. The methods disclosed herein may also incorporate steps associated with evaluating the urine of a sample for the presence of an estrogen metabolite and/or luteinizing hormone.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and/or a base unit for obtaining a sensitive read-out of the immunoassay results. The immunoassay devices and methods may utilize a competitive binding-like assay and a sandwich binding assay to detect at least progesterone or analytes of progesterone in a sample.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and/or a base unit for obtaining a sensitive read-out of the immunoassay results. The immunoassay devices and methods may utilize a competitive binding-like assay and a sandwich binding assay to detect at least progesterone or analytes of progesterone in a sample.

The present disclosure reveals the diagnostic method for the determination of multiday average molar concentration of estradiol (E2) and from this parameter, the assessment of perimenopause and menopause status in examined female subjects, based on quantitative analysis of N-glycans bound on immunoglobulin G (IgG). The diagnostic process is applicable to the female subjects of 40-55 years of age. The revealed method enables the determination of the multiday average molar concentration of estradiol (E2), which is an important diagnostic parameter hardly accessible by any known single diagnostic method applied on only one or more blood analyses.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and/or a base unit for obtaining a sensitive readout of the immunoassay results. The methods disclosed herein may also incorporate steps associated with evaluating the urine of a sample for the presence of an estrogen metabolite and/or luteinizing hormone.

An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit.

An array of methods for assessing vaginal atrophy are disclosed. The methods may be used alone or in combination with a treatment or as part of a kit.

A kit for assessing efficacy of a vaginal atrophy treatment regimen is disclosed. The kit includes a pretreatment assessment method for vaginal atrophy comprising and a topical treatment for application to the labia majora, labia minora, introitus, vagina, or combinations thereof.